Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience

Macitentan (10 mg once daily orally), a dual endothelin receptor antagonist (ERA) developed by modifying the structure of bosentan to increase the efficacity and safety, is approved for the treatment of pulmonary arterial hypertension (PAH). The pivotal SERAPHIN trial, (a landmark trial in the histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Belge, Catharina, Delcroix, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376529/
https://www.ncbi.nlm.nih.gov/pubmed/30736726
http://dx.doi.org/10.1177/1753466618823440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376529/
https://www.ncbi.nlm.nih.gov/pubmed/30736726
http://dx.doi.org/10.1177/1753466618823440

Ejemplares similares